美国 · SEC FORM 4
Atea Pharmaceuticals, Inc.
AVIR · Nasdaq · CIK 0001593899 · Healthcare · Biotechnology
内部人信号
1 位买方 · 1 条买入交易行 · $25.4K 买入总额
为什么有这个信号?
评分构成
每条进度条表示其对当前分数的贡献;权重和公式保持不变。
哪些因素限制了当前分数?
- ⚠ Cluster breadth is moderate · 1 insider(s), not 4+
- ⚠ Purchase size is modest relative to the model scale
- ⚠ Purchase activity is becoming less recent
- ✓ 角色得分高 · 买入者中职位最高的是:Director
Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.
US-v1.2 按当前 180 天规则给合资格的股票买入打分。分数只表示研究的先后,不是收益预测或概率。回测没有显示美国分数越高、之后的表现越好。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。
—
买方广度与集中度
Roles in the peak window: Director. Concentration uses priced qualifying P lines only and does not change the saved score.
信号历史
最新留档分数
- 41.2
- 41.1
- 41.1
- 41.1
- 41.0
Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
市场背景补充近期价格表现与风险信息,不影响内部人信号。
价格表现
- 1M
- -0.6%
- 3M
- +8.6%
- 6M
- -9.2%
- 12M
- +66.1%
波动率与流动性
- 波动率
- 47.2%
- Beta
- —
- 平均每日成交额
- USD 1.5M
估值
- 市值
- USD 413.1M
- P/E
- —
基本面
- 利润率
- —
- ROE
- -57.4%
- 细分行业
- Biotechnology
市场数据
价格数据截至:2026-10-11 · 价格来源:OpenBB/yfinance; 成交量来自 本机价格缓存 (yfinance) · 来自 SEC 申报文件:市值, ROE · 财年截止日:2025-12-31 · 市值 = 申报文件封面所列的已发行股数 × 最新收盘价。股数日期:2026-08-10 · Status: PASS
空头余额
空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。
- 空头股数
- 7,886,499
- 上期报告
- 7,630,075
- 日均成交量
- 304,918
- 回补天数
- 25.9
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-05-18 | Murphy Polly A. | 买入 (P) | Common Stock | 6,100 | USD 4.17 | USD 25,437 | SEC 申报 ↗ |
| 2025-01-16 | BERGER FRANKLIN M | 买入 (P) | Common Stock | 10,000 | USD 3.36 | USD 33,600 | SEC 申报 ↗ |
| 2025-01-16 | BERGER FRANKLIN M | 买入 (P) | Common Stock | 10,000 | USD 3.36 | USD 33,600 | SEC 申报 ↗ |
| 2025-01-15 | BERGER FRANKLIN M | 买入 (P) | Common Stock | 15,000 | USD 3.19 | USD 47,850 | SEC 申报 ↗ |
| 2025-01-15 | BERGER FRANKLIN M | 买入 (P) | Common Stock | 15,000 | USD 3.19 | USD 47,850 | SEC 申报 ↗ |
| 2021-12-20 | Murphy Polly A. | 买入 (P) | Common Stock | 12,000 | USD 8.57 | USD 102,840 | SEC 申报 ↗ |
| 2020-11-03 | Rock Springs Capital LLC; Rock Springs Capital Management LP; Rock Springs Capital Master Fund LP | 买入 (P) | Common Stock | 250,000 | USD 24.00 | USD 6,000,000 | SEC 申报 ↗ |
| 2020-11-03 | Hack Andrew A. F. | 买入 (P) | Common Stock | 250,000 | USD 24.00 | USD 6,000,000 | SEC 申报 ↗ |
| 2020-11-03 | BERGER FRANKLIN M | 买入 (P) | Common Stock | 41,666 | USD 24.00 | USD 999,984 | SEC 申报 ↗ |
Form 4 申报证据
21 transaction lines in the latest 365-day window; 90 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-18 | Polsky Bruce | 期权行权/转换 (M) | Common Stock | 29,600 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-18 | Murphy Polly A. | 期权行权/转换 (M) | Common Stock | 29,600 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-18 | Lucidi Bruno | 期权行权/转换 (M) | Common Stock | 29,600 | USD 0.00 | USD 0 | SEC 申报 ↗ |
展开近期 Form 4 证据 (21 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-18 | Polsky Bruce | 期权行权/转换 (M) | Common Stock | 29,600 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-18 | Murphy Polly A. | 期权行权/转换 (M) | Common Stock | 29,600 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-18 | Lucidi Bruno | 期权行权/转换 (M) | Common Stock | 29,600 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-18 | DUNCAN BARBARA GAYLE | 期权行权/转换 (M) | Common Stock | 29,600 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-18 | BERGER FRANKLIN M | 期权行权/转换 (M) | Common Stock | 29,600 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-18 | Adams Jerome M. | 期权行权/转换 (M) | Common Stock | 29,600 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-18 | Murphy Polly A. | 买入 (P) | Common Stock | 6,100 | USD 4.17 | USD 25,437 | SEC 申报 ↗ |
| 2026-03-11 | Corcoran Andrea | 期权行权/转换 (M) | Common Stock | 60,000 | USD 1.24 | USD 74,400 | SEC 申报 ↗ |
| 2026-02-03 | Sommadossi Jean-Pierre | 期权行权/转换 (M) | Common Stock | 300,000 | USD 1.24 | USD 372,000 | SEC 申报 ↗ |
| 2026-01-31 | Vavricka John | 期权行权/转换 (M) | Common Stock | 42,083 | USD — | USD — | SEC 申报 ↗ |
| 2026-01-31 | Vavricka John | 代扣税 (F) | Common Stock | 11,570 | USD 4.24 | USD 49,057 | SEC 申报 ↗ |
| 2026-01-31 | Sommadossi Jean-Pierre | 期权行权/转换 (M) | Common Stock | 272,983 | USD — | USD — | SEC 申报 ↗ |
| 2026-01-31 | Sommadossi Jean-Pierre | 代扣税 (F) | Common Stock | 106,093 | USD 4.24 | USD 449,834 | SEC 申报 ↗ |
| 2026-01-31 | Horga Maria Arantxa | 期权行权/转换 (M) | Common Stock | 51,283 | USD — | USD — | SEC 申报 ↗ |
| 2026-01-31 | Horga Maria Arantxa | 代扣税 (F) | Common Stock | 16,073 | USD 4.24 | USD 68,150 | SEC 申报 ↗ |
| 2026-01-31 | Hammond Janet MJ | 期权行权/转换 (M) | Common Stock | 58,050 | USD — | USD — | SEC 申报 ↗ |
| 2026-01-31 | Hammond Janet MJ | 代扣税 (F) | Common Stock | 14,136 | USD 4.24 | USD 59,937 | SEC 申报 ↗ |
| 2026-01-31 | Foster Wayne | 期权行权/转换 (M) | Common Stock | 41,333 | USD — | USD — | SEC 申报 ↗ |
| 2026-01-31 | Foster Wayne | 代扣税 (F) | Common Stock | 12,132 | USD 4.24 | USD 51,440 | SEC 申报 ↗ |
| 2026-01-31 | Corcoran Andrea | 期权行权/转换 (M) | Common Stock | 54,866 | USD — | USD — | SEC 申报 ↗ |
| 2026-01-31 | Corcoran Andrea | 代扣税 (F) | Common Stock | 16,104 | USD 4.24 | USD 68,281 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | AVIR |
| CIK | 0001593899 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 90 transaction lines from 2020-11-03 to 2026-06-18 10 P purchase lines · 14 S sale lines · 66 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.